## Heli Gao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/523743/publications.pdf

Version: 2024-02-01

840776 526287 26 739 11 27 citations h-index g-index papers 30 30 30 1439 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Frontiers in Oncology, 2022, 12, 822039.	2.8	4
2	The optimal duration of capecitabine plus temozolomide in patients with wellâ€differentiated pancreatic NETsÂwith or without maintenance therapy. Journal of Neuroendocrinology, 2022, 34, e13112.	2.6	1
3	Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. EBioMedicine, 2022, 79, 104016.	6.1	12
4	The distinctive characteristics of the micro-vasculature and immune cell infiltration in cystic pancreatic neuroendocrine tumors. Journal of Endocrinological Investigation, 2021, 44, 1011-1019.	3.3	4
5	The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Journal of Translational Medicine, 2021, 19, 301.	4.4	12
6	Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Cancers, 2021, 13, 3678.	3.7	37
7	Sequential Capecitabine/Temozolomide (CAPTEM) and Sunitinib Treatment in Patients with Metastatic Well-differentiated $G1/G2$ Pancreatic Neuroendocrine Tumors. Endocrine Practice, 2021, , .	2.1	1
8	Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?. Critical Reviews in Oncology/Hematology, 2021, 167, 103493.	4.4	4
9	Evaluation of two intensive care models in relation to successful extubation after cardiac surgery. Medicina Intensiva, 2020, 44, 27-35.	0.7	2
10	Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Experimental Hematology and Oncology, 2020, 9, 28.	5.0	21
11	Serum level of CCL2 predicts outcome of patients with pancreatic cancer. Acta Gastro-Enterologica Belgica, 2020, 83, 295-299.	1.0	7
12	Research progress and design optimization of CARâ€T therapy for pancreatic ductal adenocarcinoma. Cancer Medicine, 2019, 8, 5223-5231.	2.8	12
13	<p>The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma</p> . Cancer Management and Research, 2019, Volume 11, 3327-3337.	1.9	26
14	Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. Pancreatology, 2019, 19, 472-477.	1.1	6
15	Prognostic value of γâ€glutamyltransferaseâ€ŧoâ€albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Cancer Medicine, 2019, 8, 572-584.	2.8	18
16	Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. Cancer Letters, 2018, 412, 188-193.	7.2	42
17	Revised nodal stage for pancreatic neuroendocrine tumors. Pancreatology, 2017, 17, 599-604.	1.1	11
18	Carbohydrate antigen 19â€'9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncology Letters, 2017, 14, 6795-6800.	1.8	20

#	Article	IF	CITATIONS
19	Imaging features of intracranial psammomatous meningioma. Journal of Neuroradiology, 2017, 44, 395-399.	1.1	10
20	Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. British Journal of Surgery, 2016, 103, 1189-1199.	0.3	98
21	Wnt activation protects against neomycin-induced hair cell damage in the mouse cochlea. Cell Death and Disease, 2016, 7, e2136-e2136.	6.3	120
22	High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients. Brazilian Journal of Medical and Biological Research, 2015, 48, 167-173.	1.5	9
23	Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene, 2014, 33, 2728-2736.	5.9	60
24	Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene, 2014, 33, 514-524.	5.9	198
25	PO-1019â€Clinical Characteristics And Risk Factors Of Severe Respiratory Syncytial Virus-associated Acute Lower Respiratory Tract Infections In Hospitalised Infants. Archives of Disease in Childhood, 2014, 99, A583.1-A583.	1.9	0
26	A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC) Journal of Clinical Oncology, 2011, 29, 284-284.	1.6	2